Phase I Study of T Cells Expressing an Anti-CD19 and Anti-CD20 Bispecific Chimeric Receptor in Patients With B Cell Malignancies

Trial Profile

Phase I Study of T Cells Expressing an Anti-CD19 and Anti-CD20 Bispecific Chimeric Receptor in Patients With B Cell Malignancies

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Sep 2017

At a glance

  • Drugs Anti-CD19-anti-CD20-bispecific-chimeric-antigen-receptor-T-cell-therapeutics-Beijing-Doing-Biomedical (Primary)
  • Indications Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors Beijing Doing Biomedical
  • Most Recent Events

    • 09 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top